Login to Your Account

Keryx Aiming for 2012 NDA

Zerenex Clears First Phase III Hurdle; Secondary Data Wow

By Jennifer Boggs

Wednesday, December 1, 2010
Keryx Biopharmaceuticals Inc.'s iron-based phosphate binder Zerenex (ferric citrate) met the primary and key secondary endpoints in a short-term Phase III trial in hyperphosphatemia in dialysis patients, results that bode well for the ongoing long-term study as well as for the drug's potential in the $1.5 billion phosphate binder market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription